SINGAPORE, 14 APRIL 2022: Us2.ai, the Singapore-based medtech developers of FDA- cleared AI software that, for the first time ever, fully automates a complete echocardiography (heart ultrasound) report, today announced...
Athersys is a clinical-stage biotechnology company that has established a pipeline of therapeutic product development programs in multiple disease indications. The company’s product portfolio consists of MultiStem, a non-embryonic stem cell-based approach for treating disease indications in the areas of inflammatory and immune, neurological and cardiovascular disease.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.